International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)

Status: Recruiting
Location: See location...
Study Type: Observational

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.

Participation Requirements
Sex: All
Healthy Volunteers: Accepts Healthy Volunteers

• Known or suspected PPB or related thoracic tumor

• Known or suspected sex-cord stromal tumor including Sertoli-Leydig cell tumor and gynandroblastoma (males or females)

• Other known or suspected DICER1-related condition including ovarian sarcoma, cystic nephroma, renal sarcoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma and others

• Individuals with known or suspected DICER1 pathogenic variation regardless of whether they have an established DICER1-associated condition

• Informed consent by patient/ or parent/guardian (also, where appropriate: assent and HIPAA consent)

United States
Children's Minnesota
Contact Information
Kris Ann P Schultz, MD
Anne K Harris, MPH
Time Frame
Start Date: December 6, 2016
Estimated Completion Date: December 6, 2028
Target number of participants: 3400
Type I PPB
Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
Types II and III PPB
Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
Type Ir PPB
Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
DICER1 Gene or Cond Assoc with DICER1
PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
Collaborators: ResourcePath, LLC, M.D. Anderson Cancer Center, University of Texas, Washington University School of Medicine, Dana-Farber Cancer Institute, Allina Health System, Kaiser Permanente, Children's National Research Institute, Beijing Children's Hospital, Phoenix Children's Hospital, Emory University, University of California, San Francisco, University of Cambridge
Leads: Children's Hospitals and Clinics of Minnesota

This content was sourced from

Similar Clinical Trials